$125M Deal Creates Fibrx Therapeutics, Merging Skye and Redx — Skye Bioscience, Inc.

Event summary

Skye Bioscience to acquire Redx Pharma in a $125M transaction, creating Fibrx Therapeutics.
Combined company will focus on fibrosis therapeutics, led by Redx’s management team.
RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn’s disease, is the lead program with Phase 2 data expected in H2 2028.
Transaction expected to close in Q4 2026, subject to shareholder and regulatory approvals.
Skye shareholders receive contingent value rights tied to nimacimab monetization.

The big picture

The merger reflects a strategic shift for Skye Bioscience, pivoting from obesity therapeutics to fibrosis-focused drug development. Fibrx Therapeutics enters a competitive landscape with RXC008 targeting an unmet need in Crohn’s disease, but must prove its clinical and commercial potential against established players. The deal size and investor syndicate signal confidence in the fibrosis pipeline, though execution risks remain high.

What we're watching

Clinical Milestones: The pace at which RXC008 advances through Phase 2 and delivers topline data in H2 2028 will determine Fibrx’s near-term valuation.
Integration Risk: How smoothly Skye and Redx teams merge under the new Fibrx structure could impact operational efficiency and pipeline progress.
Investor Confidence: Whether the $125M financing will be sufficient to fund operations through 2029, given potential setbacks or additional clinical demands.